Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Four-year extension study of secukinumab in active rheumatoid arthritis
2012-002760-27Phase 3Terminated
- Sponsor
- Novartis
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of secukinumab in rheumatoid arthritis (RA), sponsored by Novartis. Primary endpoints: ACR20 response over time up to Month 60, ACR50 response over time up to Month 60 and 1 more. Started Aug 2012; status: terminated.
02
Drugs
secukinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-002760-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002760-27.